India's Drug Regulator Suspends License for Pres Vu Eye Drops to Replace Reading Glasses
Suspension of Pres Vu Eye Drops
The Drugs Controller General of India (DCGI) has suspended the license for Pres Vu eye drops, claiming unauthorized promotion and safety issues. Originally marketed to reduce dependence on reading glasses, this development raises questions about the product's future.
Claims Under Scrutiny
- Pres Vu was promoted as India’s first eye drop specifically for presbyopia.
- Entod Pharmaceuticals faced backlash for misleading promotional claims.
- DCGI emphasized the lack of approval for certain claims regarding the product.
Regulatory Response
The Central Drugs Standard Control Organisation (CDSCO) highlighted the need for approval on claims made about the effectiveness of Pres Vu in treating presbyopia. The regulatory body emphasized that the eye drops were only authorized for specific uses.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.